On the public citation graph

Binding Mode and Potency of N -Indolyloxopyridinyl-4-aminopropanyl-Based Inhibitors Targeting Trypanosoma cruzi CYP51

https://doi.org/10.1021/jm501568b
0 signed · 74 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/cbic.201402027openalex-snapshot
Expanding the Binding Envelope of CYP51 Inhibitors Targeting Trypanosoma cruzi with 4‐Aminopyridyl‐Based Sulfonamide Derivatives
inferredcites →https://doi.org/10.1002/jcc.20084openalex-snapshot
UCSF Chimera—A visualization system for exploratory research and analysis
inferredcites →https://doi.org/10.1006/abbi.1996.9859openalex-snapshot
Microsomal P450 2C3 Is Expressed as a Soluble Dimer inEscherichia coliFollowing Modifications of Its N-terminus
inferredcites →https://doi.org/10.1016/j.bmc.2013.01.050openalex-snapshot
Design, structure–activity relationship and in vivo efficacy of piperazine analogues of fenarimol as inhibitors of Trypanosoma cruzi
inferredcites →https://doi.org/10.1016/j.bmcl.2009.10.029openalex-snapshot
Isoquinoline-based analogs of the cancer drug clinical candidate tipifarnib as anti-Trypanosoma cruzi agents
inferredcites →https://doi.org/10.1016/j.chembiol.2007.10.011openalex-snapshot
Sterol 14α-Demethylase as a Potential Target for Antitrypanosomal Therapy: Enzyme Inhibition and Parasite Cell Growth
inferredcites →https://doi.org/10.1016/j.ijpddr.2011.12.002openalex-snapshot
Recent developments in sterol 14-demethylase inhibitors for Chagas disease
inferredcites →https://doi.org/10.1016/j.ijpddr.2012.06.001openalex-snapshot
CYP51 structures and structure-based development of novel, pathogen-specific inhibitory scaffolds
inferredcites →https://doi.org/10.1016/s0140-6736(10)60061-xopenalex-snapshot
Chagas disease
inferredcites →https://doi.org/10.1021/cr5003134openalex-snapshot
Drug Strategies Targeting CYP51 in Neglected Tropical Diseases
inferredcites →https://doi.org/10.1021/jm050441zopenalex-snapshot
The Protein Farnesyltransferase Inhibitor Tipifarnib as a New Lead for the Development of Drugs against Chagas Disease
inferredcites →https://doi.org/10.1021/jm2015809openalex-snapshot
Analogues of Fenarimol Are Potent Inhibitors of Trypanosoma cruzi and Are Efficacious in a Murine Model of Chagas Disease
inferredcites →https://doi.org/10.1021/jm400012eopenalex-snapshot
Antitrypanosomal Lead Discovery: Identification of a Ligand-Efficient Inhibitor of Trypanosoma cruzi CYP51 and Parasite Growth
inferredcites →https://doi.org/10.1021/jm401067sopenalex-snapshot
Rational Development of 4-Aminopyridyl-Based Inhibitors Targeting Trypanosoma cruzi CYP51 as Anti-Chagas Agents
inferredcites →https://doi.org/10.1021/jm401610copenalex-snapshot
Two Analogues of Fenarimol Show Curative Activity in an Experimental Model of Chagas Disease
inferredcites →https://doi.org/10.1021/jm500448uopenalex-snapshot
4-Aminopyridyl-Based CYP51 Inhibitors as Anti- Trypanosoma cruzi Drug Leads with Improved Pharmacokinetic Profile and in Vivo Potency
inferredcites →https://doi.org/10.1021/jm801313topenalex-snapshot
Rational Modification of a Candidate Cancer Drug for Use Against Chagas Disease
inferredcites →https://doi.org/10.1021/jm9013136openalex-snapshot
Second Generation Analogues of the Cancer Drug Clinical Candidate Tipifarnib for Anti-Chagas Disease Drug Discovery
inferredcites →https://doi.org/10.1021/ml500010mopenalex-snapshot
R -Configuration of 4-Aminopyridyl-Based Inhibitors of CYP51 Confers Superior Efficacy Against Trypanosoma cruzi
inferredcites →https://doi.org/10.1073/pnas.0306241101openalex-snapshot
Automated protein crystal structure determination using elves
inferredcites →https://doi.org/10.1073/pnas.2535442100openalex-snapshot
A class of sterol 14-demethylase inhibitors as anti- Trypanosoma cruzi agents
inferredcites →https://doi.org/10.1074/jbc.m109.067470openalex-snapshot
Crystal Structures of Trypanosoma brucei Sterol 14α-Demethylase and Implications for Selective Treatment of Human Infections
inferredcites →https://doi.org/10.1074/jbc.m110.133215openalex-snapshot
Structural Insights into Inhibition of Sterol 14α-Demethylase in the Human Pathogen Trypanosoma cruzi
inferredcites →https://doi.org/10.1074/jbc.m113.497990openalex-snapshot
Complexes of Trypanosoma cruzi Sterol 14α-Demethylase (CYP51) with Two Pyridine-based Drug Candidates for Chagas Disease
inferredcites →https://doi.org/10.1093/infdis/jit042openalex-snapshot
VNI Cures Acute and Chronic Experimental Chagas Disease
inferredcites →https://doi.org/10.1107/s0907444904019158openalex-snapshot
Coot : model-building tools for molecular graphics
inferredcites →https://doi.org/10.1107/s0907444994003112openalex-snapshot
The CCP4 suite: programs for protein crystallography
inferredcites →https://doi.org/10.1107/s0907444996012255openalex-snapshot
Refinement of Macromolecular Structures by the Maximum-Likelihood Method
inferredcites →https://doi.org/10.1128/aac.00070-13openalex-snapshot
In Vitro and In Vivo Studies of the Antiparasitic Activity of Sterol 14α-Demethylase (CYP51) Inhibitor VNI against Drug-Resistant Strains of Trypanosoma cruzi
inferredcites →https://doi.org/10.1128/aac.00281-10openalex-snapshot
A Nonazole CYP51 Inhibitor Cures Chagas’ Disease in a Mouse Model of Acute Infection
inferredcites →https://doi.org/10.1128/aac.00311-07openalex-snapshot
Small-Molecule Scaffolds for CYP51 Inhibitors Identified by High-Throughput Screening and Defined by X-Ray Crystallography
inferredcites →https://doi.org/10.1128/aac.06244-11openalex-snapshot
Pharmacological Characterization, Structural Studies, and In Vivo Activities of Anti-Chagas Disease Lead Compounds Derived from Tipifarnib
inferredcites →https://doi.org/10.1128/aac.48.3.804-808.2004openalex-snapshot
Pharmacokinetics of Posaconazole Coadministered with Antacid in Fasting or Nonfasting Healthy Men
inferredcites →https://doi.org/10.1191/0960327106het653oaopenalex-snapshot
Toxic Side Effects of Drugs Used to Treat Chagas’ Disease (American Trypanosomiasis)
inferredcites →https://doi.org/10.1371/journal.pntd.0000372openalex-snapshot
Trypanosoma cruzi CYP51 Inhibitor Derived from a Mycobacterium tuberculosis Screen Hit
inferredcites →https://doi.org/10.1371/journal.pntd.0000651openalex-snapshot
Structural Characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei Bound to the Antifungal Drugs Posaconazole and Fluconazole
inferredcites →https://doi.org/10.1371/journal.pntd.0001298openalex-snapshot
Activity In Vivo of Anti-Trypanosoma cruzi Compounds Selected from a High Throughput Screening
inferredcites →https://doi.org/10.1371/journal.pntd.0001736openalex-snapshot
Diverse Inhibitor Chemotypes Targeting Trypanosoma cruzi CYP51
inferredcites →https://doi.org/10.1371/journal.pntd.0003293openalex-snapshot
Correction: Activity In Vivo of Anti-Trypanosoma cruzi Compounds Selected from a High Throughput Screening
inferredcites →https://doi.org/10.1590/s0036-46652002000100006openalex-snapshot
Long term evaluation of etiological treatment of Chagas disease with benznidazole
inferredcites →https://doi.org/10.1590/s0074-02762009000900034openalex-snapshot
Two approaches to discovering and developing new drugs for Chagas disease
inferredcites →https://doi.org/10.1590/s0074-02762009000900042openalex-snapshot
The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease
inferredcites →https://doi.org/10.2165/11319340-000000000-00000openalex-snapshot
Pharmacokinetic/Pharmacodynamic Profile of Posaconazole
inferredcites →https://doi.org/10.2174/156802611796575894openalex-snapshot
Trypanocidal Activity of Nitroaromatic Prodrugs: Current Treatments and Future Perspectives
inferredcites →https://doi.org/10.2174/156802611796575902openalex-snapshot
Sterol 14alpha-Demethylase (CYP51) as a Therapeutic Target for Human Trypanosomiasis and Leishmaniasis
inferredcites →https://doi.org/10.3762/bjoc.9.3openalex-snapshot
Chemical–biological characterization of a cruzain inhibitor reveals a second target and a mammalian off-target

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4820110openalex-extracted
Diversity-Oriented Repurposing of Pyrimidin-4-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)benzenesulfonamides as Promising Antifungals that inhibit Ergosterol Biosynthesis of Candida albicans
inferred← citeshttps://doi.org/10.1002/cbdv.202100362openalex-snapshot
γ‐Lactones from Persea americana and Persea fulva – in Vitro and in Silico Evaluation of Trypanosoma cruzi Activity
inferred← citeshttps://doi.org/10.1002/med.22005openalex-snapshot
Experimental structure based drug design (SBDD) applications for anti‐leishmanial drugs: A paradigm shift?
inferred← citeshttps://doi.org/10.1002/slct.202302697openalex-snapshot
The Importance of the Piperazine Ring for the Development of Trypanomicide Compounds
inferred← citeshttps://doi.org/10.1007/s00436-018-6084-3openalex-snapshot
Experimental models in Chagas disease: a review of the methodologies applied for screening compounds against Trypanosoma cruzi
inferred← citeshttps://doi.org/10.1007/s10847-022-01162-1openalex-snapshot
NMR studies of Sugammadex formulations complexes with steroidal neuromuscular blockers drugs Rocuronium and Vecuronium
inferred← citeshttps://doi.org/10.1007/s11030-020-10113-2openalex-snapshot
Planning new Trypanosoma cruzi CYP51 inhibitors using QSAR studies
inferred← citeshttps://doi.org/10.1016/j.bioorg.2025.109046openalex-snapshot
A comprehensive review of targeting sterol 14α-demethylase and sterol C-24 methyl transferase, two pivotal proteins in Leishmania, as compelling therapeutic targets
inferred← citeshttps://doi.org/10.1016/j.compbiolchem.2017.01.005openalex-snapshot
Response surface methodology in drug design: A case study on docking analysis of a potent antifungal fluconazole
inferred← citeshttps://doi.org/10.1016/j.lddd.2026.100340openalex-snapshot
In vitro, in vivo, and computational insights into oxadiazole-pyrimidine-linked thiocoumarins as potent therapeutics for chagas disease
inferred← citeshttps://doi.org/10.1016/j.parint.2020.102225openalex-snapshot
In vitro evaluation of antitrypanosomal activity and molecular docking of benzoylthioureas
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.2c01451openalex-snapshot
Novel Aryl Alkamidazole Derivatives as Multifunctional Antifungal Inhibitors: Design, Synthesis, and Biological Evaluation
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.6b00442openalex-snapshot
Hit-to-Lead Optimization of a Novel Class of Potent, Broad-Spectrum Trypanosomacides
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.8b01464openalex-snapshot
Design, Synthesis, and Biological Evaluation of New 1-(Aryl-1H-pyrrolyl)(phenyl)methyl-1H-imidazole Derivatives as Antiprotozoal Agents
inferred← citeshttps://doi.org/10.1021/acschembio.6b01037openalex-snapshot
Rapid Chagas Disease Drug Target Discovery Using Directed Evolution in Drug-Sensitive Yeast
inferred← citeshttps://doi.org/10.1038/s41598-024-84697-2openalex-snapshot
In vitro assays identified thiohydantoins with anti-trypanosomatid activity and molecular modelling studies indicated possible selective CYP51 inhibition
inferred← citeshttps://doi.org/10.1080/1061186x.2018.1536982openalex-snapshot
Heme metabolism as a therapeutic target against protozoan parasites
inferred← citeshttps://doi.org/10.1080/17568919.2024.2359361openalex-snapshot
Aminopyridines in the development of drug candidates against protozoan neglected tropical diseases
inferred← citeshttps://doi.org/10.1124/molpharm.120.000092openalex-snapshot
Domain-Swap Dimerization of Acanthamoeba castellanii CYP51 and a Unique Mechanism of Inactivation by Isavuconazole
inferred← citeshttps://doi.org/10.1371/journal.pntd.0006104openalex-snapshot
CYP51 is an essential drug target for the treatment of primary amoebic meningoencephalitis (PAM)
inferred← citeshttps://doi.org/10.1371/journal.pntd.0006132openalex-snapshot
4-aminopyridyl-based lead compounds targeting CYP51 prevent spontaneous parasite relapse in a chronic model and improve cardiac pathology in an acute model of Trypanosoma cruzi infection
inferred← citeshttps://doi.org/10.17760/d20128894openalex-snapshot
Design, synthesis, and evaluation of inhibitors of trypanosome growth for neglected disease drug discovery
inferred← citeshttps://doi.org/10.2174/1386207322666191010144111openalex-snapshot
Current Approaches to Drug Discovery for Chagas Disease: Methodological Advances
inferred← citeshttps://doi.org/10.2174/1389450123666220509202352openalex-snapshot
Hybrid-Compounds Against Trypanosomiases
inferred← citeshttps://doi.org/10.2174/1570180816666190305141733openalex-snapshot
Anti-Trypanosoma cruzi Activity and Molecular Docking Studies of 1Hpyrazolo[ 3, 4-b]pyridine Derivatives
inferred← citeshttps://doi.org/10.2174/1574891x11666161024165304openalex-snapshot
Targets and Patented Drugs for Chemotherapy of Chagas Disease in the Last 15 Years-Period
inferred← citeshttps://doi.org/10.2174/9789815165258123120004openalex-snapshot
Anti-trypanosomatid Drugs/Candidates in Clinical Trials: What's New and What's Missing?
inferred← citeshttps://doi.org/10.3390/molecules27010319openalex-snapshot
Recent Progress in the Development of Indole-Based Compounds Active against Malaria, Trypanosomiasis and Leishmaniasis
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.